Brief: Almirall signs license deal with Sun Pharma for psoriasis treatment

Sun Pharma Advanced Research

27/07/2016 16:35

July 27 (Reuters) - Almirall SA  ALM.MC : 
    * Says enters into a license agreement with Sun Pharma 
Industries  SUN.NS  for tildrakizumab in Europe for psoriasis 
    * Says to pay Sun Pharma an initial upfront payment of $50 
million 
    * Says Sun Pharma will be eligible to get milestone 
payments, sales milestone payments and royalties on net sales 
    * Says phase-3 studies of tildrakizumab have recently been 
completed 
 
     
Source text for Eikon:  ID:nCNM4C7tkf , http://bit.ly/2abGfVt 
     
Further company coverage:  ALM.MC  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))